Table 4.
Relationship Between BRAF V600E Mutation and Tumor Recurrence in Low-Risk Clinicopathologic Categories of PTC
| Clinicopathologic Category | Tumor Recurrence |
Person- Years of Follow-Up | Recurrence Rates |
Model One* |
Model Two† |
Model Three‡ |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
BRAF V600E Positive |
BRAF V600E Negative |
BRAF V600E Positive |
BRAF V600E Negative |
P§ | ||||||||||||
| No. | % | No. | % | Per 1,000 Person-Years | 95% CI | Per 1,000 Person-Years | 95% CI | HR | 95% CI | HR | 95% CI | HR | 95% CI | |||
| Stage I | 66 of 547 | 12.1 | 53 of 726 | 7.3 | 5,941.8 | 25.61 | 20.12 to 32.60 | 15.75 | 12.03 to 20.62 | .008 | 1.61 | 1.12 to 2.31 | 1.58 | 1.07 to 2.34 | 1.56 | 1.04 to 2.34 |
| Stage II | 19 of 92 | 20.6 | 13 of 142 | 9.2 | 919.5 | 54.99 | 35.08 to 86.22 | 22.65 | 13.15 to 39.00 | .01 | 2.44 | 1.20 to 4.97 | 3.22 | 1.41 to 7.34 | 4.45 | 1.70 to 11.67 |
| Tumor ≤ 1.0 cm | 39 of 219 | 17.8 | 18 of 315 | 5.7 | 2,270.2 | 43.85 | 32.04 to 60.02 | 13.04 | 8.21 to 20.69 | < .001 | 3.33 | 1.90 to 5.84 | 2.74 | 1.50 to 5.02 | 2.40 | 1.00 to 5.75 |
Abbreviations: HR, hazard ratio; PTC, papillary thyroid cancer.
*
Model one was unadjusted.
†
Model two was adjusted for patient age and sex and stratified by medical center.
‡
Model three was additionally adjusted for tumor size, extrathyroidal invasion, lymph node metastasis, and multifocality (and PTC subtypes for all-types group).
§
P values from Poisson regressions comparing BRAF mutation–positive and –negative groups.